SYRE logo

SYRE Spyre Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$101.46
+7.65 (+8.15%)

Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for add…

Market Cap: $9.64Bwww.spyre.com

Price

No data yet.

Social Signal Score

54
5d
—
30d
60
4 mentions
—
60d
52
13 mentions
—
90d
50
22 mentions
—
news: 15 · rss: 7

Analyst Ratings

13 analysts
Buyconsensus
Strong Buy 0Buy 12Hold 1Sell 0Strong Sell 0
Avg price target$121.5+19.8%
Low $115Median $120.5High $130
Current Consensus

Revenue

$0.00-100.00%
$0.00$30.16M$60.33M$90.49M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-2.07
$-2.29–$-1.59
8 analysts
FY2026
$-3.12
$-3.43–$-2.84
10 analysts
FY2027
$-3.81
$-4.59–$-3.41
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Cameron Turtle
Sector
Healthcare
Industry
Biotechnology
Employees
125
Beta
3.23
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
116.93
www.spyre.com